Related by context. All words. (Click for frequent words.) 73 neoplasms 73 grade prostatic intraepithelial 71 PCa 71 grade cervical intraepithelial 70 prostate cancer CaP 70 urothelial carcinoma 70 GISTs 69 neoplasm 69 intraepithelial neoplasia 69 prostate carcinoma 69 adenoma 69 neoplasia PIN 69 precursor lesions 69 HGPIN 69 prostate adenocarcinoma 68 adenomatous polyps 68 cervical carcinoma 68 breast carcinoma 68 intestinal metaplasia 68 adenocarcinomas 67 epithelial tumors 67 mucinous 67 carcinomas 67 neoplastic lesions 67 transitional cell carcinoma 67 androgen deprivation 67 lobular carcinoma 67 carcinoma 67 cervical intraepithelial neoplasia 66 endometrial carcinoma 66 epithelial ovarian cancer 66 CIN2 + 66 lymph node metastasis 66 colorectal carcinoma 66 leiomyomas 66 endometrial cancers 66 renal tumors 66 gastric adenocarcinoma 66 gastric carcinoma 66 neoplasias 66 colorectal polyps 66 malignancy 66 MALT lymphoma 66 situ LCIS 65 cutaneous melanoma 65 pancreatic adenocarcinoma 65 Squamous 65 malignancies 65 ASCUS 65 neoplastic 65 premalignant 65 bladder cancers 65 colorectal neoplasms 65 advanced adenoma 65 paragangliomas 65 CIN3 65 myeloproliferative disorders 65 fallopian tube carcinoma 65 resectable 65 metastatic bladder 65 metastatic lesions 65 nodal metastasis 65 histological subtype 65 premalignant lesions 65 metaplasia 64 colorectal adenomas 64 liver metastasis 64 pheochromocytoma 64 hyperplastic 64 basal cell carcinoma BCC 64 nonmetastatic 64 hepatocellular carcinoma 64 papillary 64 lung carcinomas 64 adenomas 64 seminoma 64 cystectomy 64 grade dysplasia 64 lymph node metastases 64 invasive ductal 64 pT2 64 prostate cancer CRPC 64 ovarian carcinoma 64 node metastases 64 ADPKD 64 colorectal adenoma 64 hepatocellular carcinoma HCC 64 serous ovarian cancer 64 atrophic gastritis 64 atypical hyperplasia 64 invasive carcinoma 64 malignant lymphoma 64 thyroid nodules 64 grade gliomas 64 pleomorphic 64 advanced adenomas 64 pelvic lymphadenectomy 64 lymphadenectomy 64 pCR 64 metastases 64 endometrioid 64 hematopoietic cancers 64 relapsed ovarian cancer 64 myeloproliferative diseases 64 distant metastasis 64 seminomas 63 hepatocellular carcinomas 63 osteosarcomas 63 histologic subtype 63 hamartomas 63 SLNB 63 colorectal cancer CRC 63 EBRT 63 Leydig cell 63 hepatocellular cancer 63 transurethral resection 63 proximal colon 63 T1a 63 uveal melanoma 63 HNSCC 63 endometrial hyperplasia 63 metachronous 63 biochemical recurrence 63 paraganglioma 63 atypical ductal hyperplasia 63 MGUS 63 gastric cancers 63 CaP 63 prostate cancer PCa 63 colorectal tumors 63 lymphadenopathy 63 recurrent VTE 63 situ CIS 63 malignant lesions 63 epithelial ovarian 63 nonmelanoma skin cancers 63 ovarian tumors 63 papillary renal cell carcinoma 63 grade cervical dysplasia 63 mesotheliomas 63 chlamydial infection 63 superficial bladder cancer 63 lymph node dissection 63 intravesical therapy 63 acute GvHD 63 contralateral breast 63 urothelial 63 ductal 63 serrated polyps 63 grade glioma 63 ductal breast cancer 63 lobular carcinomas 63 prostatic intraepithelial neoplasia 62 curative resection 62 C. trachomatis 62 pituitary adenomas 62 T2DM 62 advanced neoplasia 62 Papillary 62 precancerous cervical 62 cytoreductive surgery 62 pathologic 62 operable breast cancer 62 ductal cancer 62 renal cell carcinomas 62 chromosomal rearrangement 62 metastatic malignant 62 serum prostate 62 histologically confirmed 62 grade squamous intraepithelial 62 carcinoid tumor 62 tumor recurrence 62 micrometastases 62 nodal metastases 62 papillomas 62 metastatic renal cell carcinoma 62 lipomas 62 pathologic diagnosis 62 varices 62 gastric cardia 62 atypia 62 colonic polyps 62 thymoma 62 Adenomas 62 prostate cancers 62 colorectum 62 adenomatous 62 cyclin E 62 Radical prostatectomy 62 distant metastases 62 pulmonary metastases 62 thyroid carcinoma 62 EGFR mutations 62 pT3 62 clinically localized prostate 62 skeletal metastases 62 cytoreduction 62 Hurthle cell 62 bladder carcinoma 62 malignant lymphomas 62 hyperplastic polyps 62 cervical lymph nodes 62 prostate cancer AIPC 62 malignant neoplasms 62 small lymphocytic lymphoma 62 leiomyoma 62 IDH mutations 62 CIN2 62 tumoral 62 NMIBC 62 thromboembolic complications 62 urothelial bladder cancer 62 metastatic RCC 62 poorer prognosis 62 geographic atrophy 62 hepatic metastases 62 rebleeding 62 HER2 overexpression 62 hypercalcemia 62 microsatellite instability 62 cholelithiasis 62 squamous cell carcinoma SCC 62 radical prostatectomy RP 61 follicular thyroid cancer 61 urine cytology 61 nonalcoholic steatohepatitis NASH 61 nonmelanoma skin cancer 61 severe neutropenia 61 chemopreventive agent 61 squamous 61 lymphocytosis 61 malignant polyps 61 cervical lesions 61 esophageal cancers 61 pancreatic carcinoma 61 Mitomycin C 61 meningiomas 61 histologic 61 cholangiocarcinoma 61 bone metastasis 61 recurrent ovarian 61 chemoresistant 61 castrate resistant prostate cancer 61 breast carcinomas 61 lymphoproliferative disorders 61 invasive carcinomas 61 CMV disease 61 thromboembolic events 61 Barrett esophagus BE 61 Sjögren syndrome 61 Candida infection 61 castration resistant 61 BRCA2 mutation carriers 61 carcinoids 61 androgen deficiency 61 invasive candidiasis 61 stage IIIB 61 VUR 61 malignant growths 61 colorectal adenocarcinoma 61 histologically 61 adjuvant therapy 61 immunocompetent 61 adrenalectomy 61 urothelial cancer 61 Fas ligand 61 PAOD 61 nodular 61 Toxicities 61 chronic periodontitis 61 androgen independent 61 orchiectomy 61 TT genotype 61 completely resected 61 lymph node involvement 61 essential thrombocythemia 61 adenocarcinoma 61 metastatic cancers 61 K ras mutations 61 hyperplasia 61 gastrointestinal cancers 61 neuroblastomas 61 sarcomatoid 61 anaplastic 61 ductal carcinomas 61 thyrotoxicosis 61 metastatic prostate cancer 61 gastric atrophy 61 pre malignant lesions 61 metastatic malignant melanoma 61 malignant transformation 61 mRCC 61 osteochondroma 61 prostate pancreatic 61 neoadjuvant 61 myelofibrosis polycythemia vera 61 metastatic 61 solar keratoses 61 Sezary syndrome 60 undergoing radical prostatectomy 60 lobular cancer 60 axillary lymph node 60 FGFR2 60 chemoradiotherapy 60 Endometrial 60 malignant pleural mesothelioma 60 choroidal neovascularization 60 solar keratosis 60 gemcitabine Gemzar 60 colorectal liver metastases 60 cytotoxic chemotherapy 60 esophageal squamous cell carcinoma 60 carotid plaques 60 hepatocellular 60 renal carcinoma 60 metastatic gastric 60 cytologic 60 lobular 60 metastatic cancer 60 cell lymphoma ALCL 60 hematologic toxicity 60 precancerous cervical lesions 60 malignant nodules 60 ALCL 60 hepatic fibrosis 60 cell carcinoma 60 soft tissue sarcomas 60 NSCLC 60 ALND 60 Carcinoma 60 extracapsular extension 60 pyelonephritis 60 acute leukemias 60 malignant neoplasm 60 Adenocarcinoma 60 testicular germ cell 60 acute myelogenous leukemia AML 60 thyroglobulin 60 premalignant lesion 60 thromboembolism 60 platinum refractory 60 gastrointestinal stromal tumor 60 castrate resistant 60 peritoneal carcinomatosis 60 testicular tumors 60 BRCA1 mutation carriers 60 HBeAg 60 non squamous NSCLC 60 receptor tyrosine kinase inhibitor 60 Adjuvant chemotherapy 60 epithelioid 60 prostatic hyperplasia 60 cytoreductive nephrectomy 60 tumor necrosis 60 PNET 60 etiologic agent 60 Carcinomas 60 oropharyngeal cancer 60 POAG 60 sCJD 60 pheochromocytomas 60 radioiodine therapy 60 breast lesions 60 fibroadenomas 60 recurrent glioblastoma multiforme 60 recurrent ovarian cancer 60 total thyroidectomy 60 mammary tumors 60 cervical precancer 60 leukemia AML 60 thromboembolic disease 60 lung metastasis 60 variceal hemorrhage 60 micrometastasis 60 duplex ultrasonography 60 Metastatic 60 biliary tract cancer 60 candidemia 60 etiologic 60 R0 resection 60 malignant ovarian 60 KRAS mutations 60 neoadjuvant therapy 60 serum PSA 60 BRCA mutation carriers 60 abnormal cytology 60 liver metastases 60 contrast induced nephropathy 60 seminal vesicle 60 perianal 60 polyposis 60 5FU 60 pancreatic cancers 60 malignant prostate 60 metastatic disease 60 flutamide 60 radical nephrectomy 59 gastric cancer 59 biochemical relapse 59 radical cystectomy 59 subclinical 59 adnexal mass 59 idiopathic myelofibrosis 59 neurofibromas 59 HBeAg negative 59 ultrasonographic 59 prognostic variables 59 medullary thyroid cancer 59 LHRH receptor positive 59 sonographic appearance 59 allograft rejection 59 Hashimoto thyroiditis 59 pleural mesothelioma 59 transgene expression 59 astrocytomas 59 gene rearrangements 59 recurrent metastatic 59 PCNSL 59 ischemic lesions 59 urolithiasis 59 neuroendocrine carcinoma 59 ALK mutations 59 bladder tumors 59 BRCA mutations 59 arterial calcification 59 hamartoma 59 cell carcinomas 59 extracranial 59 axillary lymph nodes 59 squamous cell cancers 59 adjuvant chemotherapy 59 histopathologic examination 59 choriocarcinoma 59 myelodysplastic syndrome MDS 59 CMV infection 59 lung nodules 59 B7 H3 59 HER2 positive cancers 59 melanocytic nevi 59 HBV infection 59 dysglycemia 59 localized prostate cancer 59 rectal cancers 59 hypogonadal 59 papillary thyroid carcinoma 59 basal cell nevus syndrome 59 EUS FNA 59 recurrent NSCLC 59 locoregional recurrence 59 androgen dependent 59 chlamydial 59 acute aortic dissection 59 colorectal cancer 59 metastatic colorectal 59 chromosomal mutations 59 castration resistant prostate cancer 59 hypertrophic scars 59 chemosensitivity 59 Doxil ® 59 hormone receptor positive 59 prognostic significance 59 astrocytoma 59 monoclonal gammopathy 59 Leukemias 59 precancers 59 trans retinoic acid 59 LSIL 59 lichen planus 59 androgen receptor AR 59 immunohistochemical staining 59 locoregional 59 colorectal neoplasia 59 N. gonorrhoeae 59 Trichomonas vaginalis 59 penetrance 59 HRCT 59 squamous cell carcinomas 59 Metastases 59 immunohistochemical 59 carotid stenosis 59 adjuvant radiotherapy 59 leukoencephalopathy 59 dysplastic 59 prostate carcinomas 59 recurrent prostate cancer 59 renal cell carcinoma 59 fibroma 59 neoadjuvant chemotherapy 59 cTnT 59 anterior uveitis 59 CIN3 + 59 Gliomas 59 papillary carcinoma 59 ABCB1 59 endometrial 59 Malignant Melanoma 59 PSADT 59 esophageal adenocarcinoma 59 polypectomy 59 prostatic 59 prostate specific 59 Recurrences 59 adenoma recurrence 59 liver resection 59 tumorigenicity 59 occult metastases 59 Prostatitis 59 benign neoplasms 59 HER2 negative 59 germline mutations 59 polypoid 59 gastrointestinal stromal tumors GISTs 59 fallopian tube cancers 59 ovarian lung 59 ErbB2 positive 59 mTOR inhibitors 59 asymptomatic carotid stenosis 59 colorectal cancers 59 testicular cancers 59 lobular breast cancer 59 systemic fungal infections 59 mycosis fungoides 59 nasopharyngeal carcinoma 59 immunohistochemical analysis 59 esophagogastric junction 59 cell lymphoma CTCL 59 morphologic 59 GIST tumors 59 primary hyperparathyroidism 59 carcinoid tumors 59 occlusive disease 59 Adjuvant therapy 59 urethritis 59 kinase inhibition 59 cytotoxic therapy 59 Surgical excision 59 varicoceles 59 microscopic hematuria 59 thyroid dysfunction 59 adjuvant radiation 59 prognostic indicator 59 hormone refractory 59 hematuria 59 precancer 59 normal karyotype 59 lesions 58 LUTS 58 breast endometrial 58 BRCA1 BRCA2 58 pleural effusions 58 FDG uptake 58 peritoneal cancer 58 proliferative diabetic retinopathy 58 LRP5 58 p = #.# [003] 58 specific antigen PSA 58 steatohepatitis 58 clinicopathological features 58 trastuzumab Herceptin ® 58 dysplasia 58 progesterone receptor negative 58 bevacizumab Avastin ® 58 MAPK pathway 58 vesicoureteral reflux 58 penile cancers 58 polycythemia vera PV 58 HER2 expression 58 refractory prostate cancer 58 node metastasis 58 CHEK2 58 mediated apoptosis 58 effector function 58 infarcts 58 B CLL 58 BRCA deficient 58 seminal vesicle invasion 58 pericardial effusion 58 neuroendocrine cancers 58 androgen ablation 58 prognostic biomarker 58 osteochondromas 58 HbF 58 Inhibin B 58 myeloproliferative neoplasms 58 sentinel lymph node biopsy 58 intrahepatic 58 alkylating agents 58 GSTT1 58 KRAS mutation 58 basal cell carcinomas 58 BRAF mutation 58 mycophenolate mofetil 58 supratentorial 58 hypoperfusion 58 macroalbuminuria 58 p# mutation 58 nonsmall cell lung cancer 58 polypoid lesions 58 cervical dysplasia 58 EGFR mutation 58 vulvar intraepithelial neoplasia 58 lymphomas 58 onset diabetes mellitus 58 thyrotropin 58 hormone refractory prostate cancer 58 GSTP1 58 oesophageal 58 transplantation HSCT 58 cranial irradiation 58 BCR ABL mutations 58 squamous carcinoma 58 calculi 58 varicocele 58 thromboembolic 58 HBeAg positive 58 sentinel node 58 situ DCIS 58 invasive lobular 58 subclinical hyperthyroidism 58 HER2 positive metastatic breast 58 eccrine 58 PSA nadir 58 dysplastic nevi 58 nanomolar 58 amenorrhoea 58 gadolinium enhanced 58 arterial thickening 58 diagnostic biomarker 58 HRPC 58 subependymal giant cell 58 hydronephrosis 58 prognostic indicators 58 SUVmax 58 squamous cell lung cancer 58 Nilotinib 58 esophageal carcinoma 58 tumors 58 elevated CRP 58 Doppler sonography 58 Metastatic breast cancer 58 submucosal 58 Aurora kinase 58 systemic toxicity 58 xenograft tumors 58 haematopoietic 58 leukemia ALL 58 germline mutation 58 Actinic Keratosis 58 chemoresistance 58 IgA antibodies 58 benign polyps 58 epididymitis 58 hepatic lesions 58 herpes zoster shingles 58 invasive lobular carcinoma 58 IV NSCLC 58 hyperoxaluria 58 endoscopic resection 58 axillary dissection 58 PTPN# 58 proliferative retinopathy 58 lymph node removal 58 Surgical resection 58 core needle biopsy 58 distal colon 58 carcinoid 58 differentiated thyroid 58 schwannomas 58 neuroendocrine tumors 58 T1DM 58 hepatoma 58 uterine tumors 58 steatosis 58 nephrogenic 58 endoscopic ultrasonography 58 renal fibrosis 58 HDACi 58 TNF blocker therapy 58 posaconazole 58 activating mutations 58 monocytic 58 breast tumors 58 gefitinib Iressa 58 precancerous condition 58 invasive ductal carcinoma 58 IgA deficiency 58 pre cancerous growths 58 kidney cysts 58 carcinoma HNSCC 58 periprocedural MI 58 adjuvant therapies 58 thrombophilia 58 oral squamous cell 58 noncalcified 58 ependymoma 58 rs# [001] 58 malignant pancreatic 58 mammographically 58 bacteriuria 58 biliary strictures 58 immunostaining 58 BCCs 58 LHRH agonists 58 hereditary breast cancer 58 scintigraphic 58 metastatic neuroendocrine tumors 58 carcinoma HCC 58 radiosensitivity 58 pre cancerous lesion 58 hereditary hemochromatosis 58 EGFR mutant 58 cisplatin chemotherapy 58 transplantation HCT 58 fibrinolysis 58 histopathologic 58 meningioma 58 Clusterin 58 Asymptomatic 58 histologies 58 Barrett esophagus 57 c MET 57 prostatitis 57 desmoplastic 57 NF1 57 external beam radiotherapy 57 subclinical atherosclerosis 57 neovascularisation 57 HPV# 57 follicular lymphoma FL 57 primary peritoneal 57 promoter methylation 57 T1c 57 imatinib Gleevec 57 NF kB pathway 57 resistant ovarian cancer 57 intestinal polyps 57 atherosclerotic disease 57 Glioma 57 TRUS 57 perioperative morbidity 57 definite stent thrombosis 57 androgenetic alopecia 57 parathyroid 57 mitochondrial toxicity 57 CYT# potent vascular disrupting 57 prognostic factor 57 osteopenic 57 platelet reactivity 57 splenic 57 heavily pretreated 57 incidentalomas 57 lymphoproliferative disorder 57 myocardial ischemia 57 pulmonary resection 57 benign lesions 57 radiochemotherapy 57 systemic lupus erythematosus 57 carboplatin paclitaxel 57 liver fibrosis 57 imatinib therapy 57 renal dysfunction 57 colorectal polyp 57 underwent resection 57 diffuse gastric 57 NP CRNs 57 osteoid osteoma 57 ductal adenocarcinoma 57 villous 57 HER2 + 57 invasive aspergillosis 57 ovarian cancers 57 histologic subtypes 57 lesional 57 colon carcinoma 57 β blockers 57 proto oncogene 57 Immunohistochemical staining 57 oropharyngeal 57 cerebral infarction 57 Prostatic 57 gliomas 57 anti angiogenic therapy 57 polyp recurrence 57 familial ALS 57 leukocytosis 57 lymphocytic 57 SCCHN 57 urinary tract symptoms LUTS 57 sporadic ALS 57 bronchogenic carcinoma 57 bowel cancers 57 squamous cell 57 brain metastases 57 GnRH agonists 57 genomic alterations 57 intraductal 57 pulmonary nodules 57 cisplatin resistant 57 activating mutation 57 lymphoid malignancies 57 p# mutations 57 KIT mutations 57 FGFR3 57 dysplastic lesions 57 Helicobacter pylori infection 57 metastatic pancreatic 57 HER2 positive 57 coinfection 57 unresectable tumors 57 vestibular schwannomas 57 ErbB2 57 tunica vaginalis 57 melanomas 57 diabetes mellitus DM 57 coronary artery stenosis 57 oesophageal adenocarcinoma 57 anal cancers 57 intraepithelial 57 cerebral vasospasm 57 orthotopic 57 cystic lesions 57 polycythemia vera essential thrombocythemia 57 apoptotic pathway 57 renal scarring 57 tumor progression 57 gastrointestinal stromal tumors GIST 57 myeloablative 57 bullous 57 granulomatous 57 Hodgkin lymphoma HL 57 microbleeds 57 Carcinoid tumors 57 TOP2A 57 luteinizing hormone releasing 57 ureteral 57 precancerous lesions 57 debulking surgery 57 TEAEs 57 FGFR1 57 taxane therapy 57 gemcitabine carboplatin 57 EpCAM expression 57 gastrointestinal stromal tumors 57 de ath 57 atherothrombotic 57 presymptomatic 57 pancreatic NET 57 Testicular cancer 57 intima media thickness 57 PDGFR 57 HIV HCV coinfected 57 isoenzyme 57 malignant lesion 57 sclerosing 57 localized renal 57 radiotherapy RT 57 pancreatic endocrine 57 lymphovascular invasion 57 arteriography 57 nephron sparing surgery 57 Androgen deprivation therapy 57 hirsutism 57 postoperative delirium 57 intravenous bisphosphonates 57 myeloperoxidase 57 renal pelvis 57 systemic lupus erythematosus SLE 57 metastatic lymph nodes 57 variceal bleeding 57 grade serous ovarian 57 invasive coronary angiography 57 gallstone disease 57 c KIT 57 T#I [002] 57 antigen PSA 57 neovascular 57 heavily pretreated patients 57 extramedullary 57 independent prognostic marker 57 extranodal 57 Glioblastoma Multiforme 57 node dissection 57 needle aspiration 57 tumor xenograft models 57 prostatic adenocarcinoma 57 lacunar 57 melanocytic 57 NAT2 57 Basal cell 57 hypercalciuria 57 colonoscopic 57 transarterial 57 carcinoembryonic antigen 57 hypermethylated 57 cirrhotic 57 adriamycin 57 cancers 57 thrombotic complications 57 adenomatous polyp 57 catheter angiography 57 SSc 57 BRAF mutations 57 treat benign prostatic 57 osteolytic 57 axillary lymph node dissection 57 chronic lymphocytic leukemia CLL 57 somatic mutations 57 cardiac dysfunction 57 ertapenem 57 LTBI 57 mucosal lesions 57 prostate biopsy 57 Hepatocellular Carcinoma HCC 57 aerodigestive tract 57 coronary stenosis 57 rs# [002] 57 essential thrombocythemia ET 57 cytogenetic responses 57 chemotherapy cisplatin 57 indolent lymphomas 57 postoperative chemotherapy 57 ductal lobular 57 pleurodesis 57 MLH1 57 spiral computed tomography 57 mammographic density 57 c MYC 57 NAFLD 57 epithelia 57 mammary cancers 57 helical CT 57 cerebral microbleeds 57 neoadjuvant treatment 57 TURP 57 immunoreactivity 57 detecting colorectal cancer 57 abdominal adiposity 57 malignant phenotype 57 gastroesophageal junction 57 xenograft models 57 mosaicism 57 MYCN amplification 57 prophylactic cranial irradiation 57 angiographically 57 neovascularization 57 eIF 4E 57 Endometrial cancer 57 depsipeptide 57 antiphospholipid antibodies 57 Uterine fibroids 57 glomerular filtration 57 nonalcoholic steatohepatitis 57 Haptoglobin 57 penetrating keratoplasty 57 Soft Tissue Sarcoma 57 hepatic steatosis 57 Aspergillus infections 57 cytopenias 57 dasatinib Sprycel ® 57 molecular abnormalities 57 aplasia 57 #F FDG PET 57 bilateral oophorectomy 57 DLBCL 57 antiandrogen 56 Cutaneous T 56 lung tumors 56 antiproliferative effects 56 tonsillar 56 cancer mCRC 56 cervical neoplasia 56 WT1 56 TRAIL R1 56 chemoembolization 56 paroxysmal AF 56 clinicopathologic 56 osteoblastic 56 malignant fibrous histiocytoma 56 EGFR inhibitors 56 serum testosterone 56 Pharmacokinetics PK 56 basal cell cancers 56 oophorectomy 56 Leydig cells 56 parathyroid carcinoma 56 pigmented skin lesions 56 hypermethylation 56 preoperative chemotherapy 56 neck squamous cell 56 postoperative AF 56 virologic response 56 prognostic markers 56 sonographic evaluation 56 hyperalgesia 56 Gleevec resistant 56 Neoadjuvant 56 B Cell Lymphoma 56 keloid scarring 56 HCV infection